Therefore, to treat ROS1-fusion-positive brain tumors more effectively and safely, exploring novel therapeutic target(s) of ROS1-fusion-positive tumors other than the C-terminal activation loop of ROS1 is warranted. This evidence concerns the gene ROS1 and brain neoplasm.